MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

22 12 2023 16:30:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

27 11 2023 16:30:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer

21 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

15 11 2023 16:45:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health

10 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

10 11 2023 07:30:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results

06 11 2023 08:00:01 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

02 11 2023 16:05:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12 10 2023 16:05:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering

28 9 2023 22:30:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Proposed Public Offering

28 9 2023 16:01:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

14 9 2023 16:30:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis

13 9 2023 09:10:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer

11 9 2023 07:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results

08 8 2023 08:00:01 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

17 7 2023 08:00:01 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

30 6 2023 08:00:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™

22 6 2023 03:30:00 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Supports International NASH Day on June 8

06 6 2023 08:00:02 提供 Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

01 6 2023 08:00:02 提供 Nasdaq GlobeNewswire